BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a .
BioXcel TherapeuticsFebruary 12, 2021 GMT
NEW HAVEN, Conn., Feb. 12, 2021 (GLOBE NEWSWIRE) BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the Company will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am ET to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine (“Dex”), and its potential as a treatment option for multiple neuropsychiatric conditions.
Home / Top News / BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
NEW HAVEN, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that an update from its ongoing Phase 1b/2 trial of BXCL701, the Company’s investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the virtual 2021 ASCO Genitourinary (“ASCO GU”) Cancers Symposium. ASCO GU is being held from Thursday, February 11, 2021 to Saturda
The NMIMR boss said, ‘two aspects of investigations are being conducted’.
The Noguchi Memorial Institute for Medical Research (NMIMR) University of Ghana has launched an investigation into claims that the research facility falsifies COVID-19 test results.
This was contained in a statement signed by the Director of NMIMR, Prof. Abraham Kwabena Anang.
Prof. Kwabena Anang’s statement was a reaction to a viral voice note on social media claiming tests conducted at the facility are manipulated.
The NMIMR boss said, “two aspects of investigations are being conducted.”
He said the two aspects were: NMIMR internal investigations and “External investigations will be conducted by National Security, which is in discussion with the Coordinator of National Network of COVID-19 testing Laboratories.”